Previous Close | 4.5300 |
Open | 4.4900 |
Bid | 4.4400 x 100 |
Ask | 4.5300 x 100 |
Day's Range | 4.3200 - 4.5500 |
52 Week Range | 2.0100 - 7.4500 |
Volume | |
Avg. Volume | 1,509,306 |
Market Cap | 1.197B |
Beta (5Y Monthly) | 2.02 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.2100 |
Earnings Date | Aug 01, 2024 - Aug 05, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 10.69 |
LONDON, June 14, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces three abstracts to be presented at the European Hematology Association (EHA) Congress, June 13-16, 2024. “We are looking forward to presenting longer-term data from adult patients with r/r ALL treated with obe-cel in the FELIX study,” said Dr. Christian Itin, Chief Executive Officer of Autolus. “The d
The majority of patients that responded to obe-cel showed durable responses with the potential for a long-term plateau of survival outcomes40% patients are in ongoing remission without subsequent stem cell transplant (SCT) or other interventionOngoing CAR T persistence was associated with improved event-free survivalAutolus will host a conference call and webcast to discuss the presented data on Saturday June 1, 2024 at 9:30 am EDT/8:30 am CDT/2:30 pm BST (details below) LONDON, May 31, 2024 (GL
Q1 2024 Autolus Therapeutics PLC Earnings Call